Skip to main content
      RT @CreakyJoints: The good news: Most (around 90%) of people with chronic #inflammatory disease produced antibodies afte

      CreakyJoints.org CreakyJoints

      4 years ago
      The good news: Most (around 90%) of people with chronic #inflammatory disease produced antibodies after the #COVID19 vaccine, but it was reduced compared to that of generally healthy people. #ACR21 #Plenary @alhkim https://t.co/KdWtIuuOtA
      RT @dsoulsMD: Dr. Eric Yen presenting about lupus nephritis mortality in the USA (1999-2019):
      - Increasing trend in LN m

      Danny Soulsby dsoulsMD

      4 years ago
      Dr. Eric Yen presenting about lupus nephritis mortality in the USA (1999-2019): - Increasing trend in LN mortality x5 yrs - Increased odds of death for Black pts > Latinx > API > AI/AN - Urbanization (large central metro area) independent RF + effect modifier #ACR21 https://t.co/qf61SkCqw4
      RT @ericdeinmd: #ACR21 Year in Review: TICOPSA - tight control treat to target in AxSpa does not meet primary endpoint,

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Year in Review: TICOPSA - tight control treat to target in AxSpa does not meet primary endpoint, but favorable secondary outcomes. Was the control group at academic center already receiving good tight control? @Rheumnow
      Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.
      RT @BichileT: The evolving JAK inhibitor story

      Black box Warnings regarding JAK inhibitor use and MACE, malignancy, thr

      Tanmayee Bichile, MD BichileT

      4 years ago
      The evolving JAK inhibitor story Black box Warnings regarding JAK inhibitor use and MACE, malignancy, thrombosis and mortality - full safety data remains to be examined. @ACRheum #ACRambassador #ACR21 https://t.co/imQ1LSxeXM
      RT @ericdeinmd: "We have to stop meeting like this" @DrDavidKarp @Rheumnow #ACR21. I was hoping to have some Ghirardelli

      Eric Dein ericdeinmd

      4 years ago
      "We have to stop meeting like this" @DrDavidKarp @Rheumnow #ACR21. I was hoping to have some Ghirardelli chocolates in SF... But here's hoping for Philly cheesesteaks next year 🤞
      RT @Doctorkuch: plenary I. #ACR21
      Interesting data with the delta variant from @alhkim https://t.co/oUCOXSc9wA

      Marie Kuchynski MD Doctorkuch

      4 years ago
      plenary I. #ACR21 Interesting data with the delta variant from @alhkim https://t.co/oUCOXSc9wA
      RT @ERheumat: #ACR21 #ACR2021
      Rheumatology Reproductive Health
      👉🏻 Biologics and breast milk
      👉🏻 Good vaccine

      EnvisionRheumat ERheumat

      4 years ago
      #ACR21 #ACR2021 Rheumatology Reproductive Health 👉🏻 Biologics and breast milk 👉🏻 Good vaccine response with TNFi (like with covid vaccines ) 👉🏻 ustekimumab seems safe in pregnancy 👉🏻 Tofacitinib/ small molecules may cross placenta/ be in breast milk ➡️ contraindicated in preg/BF https://t.co/qk3sLR4QHz
      RT @RichardPAConway: @alhkim presenting COVaRiPAD data on SARS-CoV-2 vaccination. Most mount immune response. Risk of po

      Richard Conway RichardPAConway

      4 years ago
      @alhkim presenting COVaRiPAD data on SARS-CoV-2 vaccination. Most mount immune response. Risk of poor response BCDT >> MMF >> GCC > MTX/AZA/JAKi/TNFi > immunocompetent. Abstr#0457 #ACR21 @RheumNow https://t.co/lf8cAEWGXf
      RT @doctorRBC: Can we predict who which PsA pts will be radiographic progressors?

      Abs#449 identified 103 candidate bio

      Robert B Chao, MD doctorRBC

      4 years ago
      Can we predict who which PsA pts will be radiographic progressors? Abs#449 identified 103 candidate biomarker peptides corresponding to 69 proteins that could ID progressors More data needed #ACR21 @RheumNow https://t.co/OLfPRNjTKV https://t.co/6UTn1J7nJH
      RT @DrPetryna: Abst0437 #ACR21 @RheumNow factors assoctd w/poor response to mRNA Covid-19 vaccine in rheum pts Rx w/Ritu

      Olga Petryna DrPetryna

      4 years ago
      Abst0437 #ACR21 @RheumNow factors assoctd w/poor response to mRNA Covid-19 vaccine in rheum pts Rx w/Rituxan: ⬆️ exposure to RTX over time, ⬇️ IgG levels prior to RTX, short interval btw RTX course & BNT162b2 vacc. RA highest&ANCA-vasculitis lowest probability for a + response. https://t.co/DsrJBlNvr7
      RT @ericdeinmd: #ACR21 Abst#0457: #COVID19 Vaccine Responses In Patients w Autoimmune Diseas
      ⭐️Prosp observ: pre-vax

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0457: #COVID19 Vaccine Responses In Patients w Autoimmune Diseas ⭐️Prosp observ: pre-vax▶️5 mo. ⭐️ 90% +Ab responses, but ⬇️ titer ⭐️MMF 21x⬇️ titer, MTX 4.4x⬇️, AZA 3.5⬇️ ⭐️BCDT: 58, JAK: 2.6, TNF 2.3 ⭐️GC ⬇️ even on <5mg! https://t.co/BGU4CP9M0s @Rheumnow #ACRbest https://t.co/7QhsTGTwnZ
      RT @RichardPAConway: Sublingual Cyclobenzaprine for fibromyalgia. It seems to improve pain, and across the board on seco

      Richard Conway RichardPAConway

      4 years ago
      Sublingual Cyclobenzaprine for fibromyalgia. It seems to improve pain, and across the board on secondary endpoints. But all by a modest effect. Big placebo response also. Not time to get overly excited yet. Abstr#0477 #ACR21 @RheumNow https://t.co/aUtwaH5oEh
      RT @bella_mehta: Wanted to highlight our work @HSpecialSurgery presented at #ACR21 using unsupervised clustering of mult

      Bella Mehta bella_mehta

      4 years ago
      Wanted to highlight our work @HSpecialSurgery presented at #ACR21 using unsupervised clustering of multimodal data - histology and ultrasound to identify phenotypes such as moderately inflammatory subtype in #osteoarthritis @RheumNow #abst0212 some features highlighted in fig https://t.co/HRzhMXctB9
      RT @MeralElRamahiMD: #ACR21 Abst#0284
      My 56 yo ♀RA pt expressed concern for developing dementia last wk. This study he

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      #ACR21 Abst#0284 My 56 yo ♀RA pt expressed concern for developing dementia last wk. This study helps recognize her RF beyond aging: ➡️ Large joint swelling (HR 2.2) ➡️ CVD (HR 2.4): stroke (HR 3.2) + chronic HF (HR 1.8) ➡️ DM (HR 1.6) #ACRBest @Rheumnow https://t.co/wsZnaLwSmD
      ×